Alopecia Areata: Infiltration of Th17 Cells in the Dermis, Particularly around Hair Follicles

Tanemura, Atsushi; Oiso, Naoki; Nakano, Mitsuru; Itoi, Saori; Kawada, Akira; Katayama, Ichiro

doi:10.1159/000350933

Cited by 62 publications

(66 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum cytokine levels of IL-17A are significantly increased, and TGFβ1 is significantly decreased, in patients with AA compared with controls [99]. In AA lesions, infiltration of CD4 + IL-17A + T H cells have been found in the dermis, particularly around hair follicles [100] [101]. Recently, a decrease in the number of skin infiltrating IL-17 + T cells was observed after topical immunotherapy with squaric acid dibutylester (SADBE) [102].…”

Section: Th17 Cells May Contribute To Alopecia Areata Developmentmentioning

confidence: 99%

The role of lymphocytes in the development and treatment of alopecia areata

Guo

Cheng

Shapiro

et al. 2015

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

SummaryAlopecia areata (AA) development is associated with both innate and adaptive immune cell activation, migration to peri-and intra-follicular regions, and hair follicle disruption. Both CD4+ and CD8+ lymphocytes are abundant in AA lesions; however, CD8+ cytotoxic T lymphocytes are more likely to enter inside hair follicles, circumstantially suggesting that they have a significant role to play in AA development. Several rodent models recapitulate important features of the human autoimmune disease and demonstrate that CD8+ cytotoxic T lymphocytes are fundamentally required for AA induction and perpetuation. However, the initiating events, the selfantigens involved, and the molecular signaling pathways, all need further exploration. Studying CD8+ cytotoxic T lymphocytes and their fate decisions in AA development may reveal new and improved treatment approaches.

show abstract

Section: Th17 Cells May Contribute To Alopecia Areata Developmentmentioning

confidence: 99%

The role of lymphocytes in the development and treatment of alopecia areata

Guo

Cheng

Shapiro

et al. 2015

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…Tanemura et al found the infiltration of CD4(+)IL-17A(+) Th17 cells in the dermis, particularly around hair follicles, in all 4 cases in their study [98].…”

Section: Secukinumabmentioning

confidence: 57%

New Modalities in the Treatment of Refractory Alopecia Areata

Kılıç¹

2017

Hair and Scalp Disorders

View full text Add to dashboard Cite

Alopecia areata (AA) is a common and complex T-cell-mediated inflammatory disorder. It may be patchy (localized), involve the entire scalp (alopecia totalis) or entire body (alopecia universalis). Alopecia totalis and universalis are often difficult to treat. Although many therapeutic options currently exist in alopecia areata, none of them are curative or preventive. Besides, none of them are approved by Food and Drug Administration (FDA). The disease unfortunately has an unpredictable course. The factors indicating a poor prognosis are the extent of hair loss at the presentation, long duration of the disease, and ophiasis pattern of hair loss. There are only a few randomized controlled studies conducted on recalcitrant AA. Recent research on immunology of hair follicle and recent developments in immunopathogenesis, together with the shared pathways of the disease with other autoimmune disorders, led investigators to focus on novel therapies that target specific immunological pathways. Herein, we will review shortly the current treatment options in recalcitrant alopecia areata based on recently published studies and then will focus on the recently developed broad-spectrum and targeted therapeutics.

show abstract

Section: Conflict Of Interest: None Declaredmentioning

confidence: 99%

“…Evidence exists that the T-helper (Th)17 cell subset is a major pathogenic protagonist in many autoimmune diseases, 1 and recent data suggest a direct contribution of interleukin (IL)-17 in the development of AA. 2,3 In this study, we investigated the characteristics of the T-cell infiltrate in AA skin biopsies from five patients undergoing SAD-BE immunotherapy and we disclosed whether changes in the infiltrating T-cell subsets, in particular Th17 cells, may correlate with the clinical response to the SADBE immunotherapy.Following written informed consent, we collected 4-mm punch skin biopsies from five patients (under institutional approval and in adherence with the principles of the Declaration of Helsinki) before the initiation of the therapy (T0) and at month 3 (T3) of treatment with SADBE for isolation of infiltrating lymphocytes (Table S1). One of the five biopsies was also analyzed for immunohistochemistry study.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effective squaric acid dibutylester immunotherapy is associated with a reduction of skin infiltrating T‐helper (Th)1 and Th17 cells in alopecia areata patients

Avitabile

Sordi

Garcovich³

et al. 2014

The Journal of Dermatology

View full text Add to dashboard Cite

Our results suggest that vincristine could be considered for refractory RDD. Because RDD is often benign and can be treated with various modalities, vincristine would be used only in refractory patients. CONFLICT OF INTEREST: None declared.Ping LIU, Pei WANG, Juan DU, Jianzhong ZHANG, Effective squaric acid dibutylester immunotherapy is associated with a reduction of skin infiltrating T-helper (Th)1 and Th17 cells in alopecia areata patientsDear Editor, Alopecia areata (AA) is a common dermatological disease characterized by non-scarring alopecia and an immune-mediated pathogenesis. Effective treatments for the disease include topical immunotherapy with squaric acid dibutylester (SADBE) or other small chemicals. However, the mechanisms involved in the beneficial effect of this therapeutic approach remain obscure. Evidence exists that the T-helper (Th)17 cell subset is a major pathogenic protagonist in many autoimmune diseases, 1 and recent data suggest a direct contribution of interleukin (IL)-17 in the development of AA. 2,3 In this study, we investigated the characteristics of the T-cell infiltrate in AA skin biopsies from five patients undergoing SAD-BE immunotherapy and we disclosed whether changes in the infiltrating T-cell subsets, in particular Th17 cells, may correlate with the clinical response to the SADBE immunotherapy.Following written informed consent, we collected 4-mm punch skin biopsies from five patients (under institutional approval and in adherence with the principles of the Declaration of Helsinki) before the initiation of the therapy (T0) and at month 3 (T3) of treatment with SADBE for isolation of infiltrating lymphocytes (Table S1). One of the five biopsies was also analyzed for immunohistochemistry study.Flow cytometric analysis of surface markers of skin infiltrating lymphocytes revealed that at T0, the infiltrate was predominantly constituted by CD4 + T cells (68 AE 21%), with a lower number of CD8 + T lymphocytes (18 AE 15%). Interestingly, at T3, we observed a decrease of CD4 + T cells (39 AE 34%) (Fig. 1a) and a clear increase of the CD8 + T-cell subpopulation (47 AE 25%, P ≤ 0.05) (Fig. 1b). In terms of cytokines production, we observed a strong decrease in the number of IL-17 + (from 24.4 AE 8.7% at T0 to 3.6 AE 3.6% at T3, Fig. 1c, P ≤ 0.05) and c-interferon (from 28.1 AE 6.8% at T0 to 18.1 AE 6.0% at T3) cells at T3 as compared with T0 ( Fig. 1d, P ≤ 0.05). The immunohistochemical staining of a skin biopsy specimen, before and after SADBE therapy, supports the data obtained from fluorescence-activated cell sorting analysis. At T0, the inflammatory infiltrate consisted primarily of peribulbar CD4 + T cells (Fig. 1e), while a lower number of CD8 + T cells was observed (Fig. 1f). Interestingly, a significant number of IL-17 + cells were widely spread around follicles (Fig. 1g). At T3, perifollicular CD4 + T cells (Fig. 1h) and IL-17 + T lymphocytes were reduced (Fig. 1j), while CD8 + T cells increased in number (Fig. 1i). This last finding, as already previously reported, 4 may be r...

show abstract

Alopecia Areata: Infiltration of Th17 Cells in the Dermis, Particularly around Hair Follicles

Cited by 62 publications

References 19 publications

The role of lymphocytes in the development and treatment of alopecia areata

The role of lymphocytes in the development and treatment of alopecia areata

New Modalities in the Treatment of Refractory Alopecia Areata

Effective squaric acid dibutylester immunotherapy is associated with a reduction of skin infiltrating T‐helper (Th)1 and Th17 cells in alopecia areata patients

Contact Info

Product

Resources

About